# Catalent, Inc. – Consensus ‘hold’ rating and -.1% Downside Potential

- Link: https://www.directorstalkinterviews.com/catalent-inc-consensus-hold-rating-and-1-downside-potential/4121185416
- Published: 2025-01-31T11:31:01+00:00
- Author: Charlotte Edwards

**Catalent, Inc.** with ticker code (CTLT) have now 5 market analysts covering the
stock. The analyst consensus now points to a rating of ‘hold’. The target price 
High/Low ranges between $63.50 and $63.00 and has a mean target at $63.40. Given
that the stocks previous close was at $63.48 this would indicate that there is a
downside of -.1%. There is a 50 day moving average of $60.41 and the 200 moving 
average now moves to $58.22. The total market capitalization for the company now
stands at 11.52B. The current share price for the company is: $63.48 USD

 The potential market cap would be $11,507,860,864 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $24.40 and
a -0.18% return on assets.

Catalent, Inc. is a provider of development and manufacturing solutions for drug,
cell and gene therapies biologics, vaccines, and consumer health products. The Company’s
segments include Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery,
and Clinical Supply Services. Its Biologics segment provides development and manufacturing
for protein, plasmid DNA mRNA, cell therapy, viral vaccines and viral-based gene
therapies. Its Softgel and Oral Technologies segment provide formulation, development,
and manufacturing services for soft capsules, as well as large-scale manufacturing
of oral solid dose forms. Its Oral and Specialty Delivery segment provides formulation
development and manufacturing across a range of technologies along with integrated
downstream clinical development and commercial supply solutions. Its Clinical Supply
Services segment provides manufacturing, packaging, storage, distribution, and inventory
management for, drugs, biologics and clinical trials.

Share on: